by Vishnuprasad on  January 22, 2015 at 7:11 PM Drug News
Mylan Loses Court Fight Over Multiple Sclerosis Drug
The Supreme Court has ruled against generic drugmaker Mylan Inc. and other firms in their challenge of Teva Pharmaceutical Industries' patents for a blockbuster multiple sclerosis drug.

The justices ruled 7-2 that a federal appeals court wrongly overturned five of Teva's patents for the drug Copaxone, which generates about $4 billion in annual sales for Teva. The majority told a lower court to reconsider a ruling invalidating the patents.

The decision allows the Israel-based company to keep its exclusive rights to Copaxone until September, delaying generic competition from Mylan and the other companies. And it gives Teva more time to shift patients to a longer acting version that won't face competition until 2030.

Source: Medindia

Most Popular on Medindia